List of Excipients in Branded Drug CEFUROXIME AXETIL

Generic Drugs Containing CEFUROXIME AXETIL

Company	Ingredient	NDC	Excipient
Major Pharmaceuticals	cefuroxime axetil	0904-7542	ALUMINUM OXIDE
Major Pharmaceuticals	cefuroxime axetil	0904-7542	CALCIUM CARBONATE
Major Pharmaceuticals	cefuroxime axetil	0904-7542	CALCIUM STEARATE
Major Pharmaceuticals	cefuroxime axetil	0904-7542	CELLULOSE, MICROCRYSTALLINE
Major Pharmaceuticals	cefuroxime axetil	0904-7542	CROSCARMELLOSE SODIUM
Major Pharmaceuticals	cefuroxime axetil	0904-7542	CROSPOVIDONE

What are the Most Frequently-Used Excipients in CEFUROXIME AXETIL?

# Of NDCs	Excipient
27	ALUMINUM OXIDE
27	CALCIUM CARBONATE
27	CALCIUM STEARATE
61	CELLULOSE, MICROCRYSTALLINE
3	CI 77891
1	COLLOIDAL SILICON DIOXIDE

Last updated: September 24, 2026

Cefuroxime axetil is an off-patent oral cephalosporin with commercial opportunity concentrated in formulation performance, pediatric usability, supply reliability, and market-specific dosage forms. The active ingredient has low aqueous solubility, variable absorption, food-dependent exposure, and suspension palatability challenges. Excipients that improve wetting, dispersion, taste, moisture control, and dose uniformity offer more practical value than attempts to extend exclusivity through the legacy active-ingredient patent estate.

Cefuroxime Axetil Excipient Strategy and Commercial Opportunities

What is the commercial profile of cefuroxime axetil?

Cefuroxime axetil is the orally administered 1-acetoxyethyl ester prodrug of cefuroxime, a second-generation cephalosporin. After absorption, esterases convert cefuroxime axetil to active cefuroxime. The product is marketed in tablets and oral suspension granules for infections caused by susceptible bacteria.

The primary commercial products are branded Ceftin in the United States and Zinnat in several international markets. Cefuroxime axetil is also sold by multiple generic manufacturers.

The formulation problem is driven by:

• Low aqueous solubility.
• Food-sensitive absorption.
• Hydrolysis of the ester prodrug.
• Sensitivity to moisture and processing conditions.
• Poor taste in pediatric liquid products.
• The need to maintain dose uniformity in a suspension.
• Different bioavailability profiles between tablets and suspension.

The opportunity is therefore formulation-led rather than molecule-led.

Which excipient functions are most important for cefuroxime axetil?

The highest-value excipient functions are wetting, disintegration, suspension stabilization, taste masking, moisture protection, and manufacturability.

Formulation objective	Relevant excipient function	Potential excipient classes
Improve dissolution	Wetting and surface-area enhancement	Sodium lauryl sulfate, poloxamers, surfactant systems
Promote tablet breakup	Superdisintegration	Croscarmellose sodium, crospovidone, sodium starch glycolate
Improve flow and compression	Diluent and glidant	Microcrystalline cellulose, mannitol, colloidal silicon dioxide
Reduce sticking	Lubrication	Hydrogenated vegetable oils, stearates, sodium stearyl fumarate
Stabilize suspension	Viscosity and particle suspension	Xanthan gum, cellulose derivatives, carbomers
Control taste	Sweetening, flavoring, coating	Sucrose, sucralose, aspartame, fruit flavors, polymer coatings
Protect against moisture	Barrier coating and packaging	Hypromellose films, moisture-barrier blisters, high-barrier bottles
Improve dose uniformity	Suspending and wetting system	Xanthan gum, povidone, surfactants, controlled particle size

Sodium lauryl sulfate can improve wetting but requires careful control because excess surfactant may affect gastrointestinal tolerability, tablet hardness, dissolution, and powder handling. A lower-surfactant formulation using particle engineering, amorphous dispersion technology, or improved granulation may have a stronger commercial profile.

How should a cefuroxime axetil tablet be formulated?

A conventional immediate-release tablet should balance rapid disintegration with protection against moisture and adequate mechanical strength.

Core tablet strategy

A practical formulation platform can include:

• Microcrystalline cellulose or mannitol as a primary diluent.
• Croscarmellose sodium or crospovidone as the disintegrant.
• Colloidal silicon dioxide as a flow aid.
• A low-level surfactant or wetting agent.
• Hydrogenated vegetable oil, sodium stearyl fumarate, or another suitable lubricant.
• A film coat based on hypromellose or a comparable polymer.

The formulation should avoid excessive hydrophobic lubrication. Over-lubrication can delay wetting and dissolution, which is a material risk for a poorly soluble prodrug.

Direct compression versus granulation

Direct compression can reduce water exposure and simplify manufacturing. Its limitations are poor flow, segregation risk, and variable content uniformity if the active ingredient has a low dose relative to excipients.

Dry granulation can improve flow without introducing significant water. Wet granulation may improve content uniformity and tablet strength but creates a greater risk of hydrolytic degradation and requires tighter control of residual moisture.

For cefuroxime axetil, dry processing or low-moisture granulation is generally more attractive when stability data show sensitivity to water activity. A high-shear wet-granulation process may remain viable if the formulation uses rapid drying and validated moisture limits.

What excipients are appropriate for cefuroxime axetil oral suspension?

The suspension is commercially important because it addresses pediatric and swallowing-limited populations. Its main technical risks are sedimentation, caking, poor redispersion, hydrolysis, and unpleasant taste.

Suspending system

Xanthan gum is a common starting point because it provides viscosity at relatively low concentrations and supports redispersion. Hydroxypropyl cellulose, hydroxyethyl cellulose, hypromellose, and microcrystalline cellulose-carboxymethylcellulose systems may also be evaluated.

The viscosity target should permit:

• Rapid redispersion after standing.
• Accurate withdrawal through an oral syringe.
• Acceptable pourability.
• Consistent dose delivery over the labeled in-use period.

A suspension that is too viscous can reduce pediatric acceptability and produce dose loss in the bottle. A system that is too thin can sediment rapidly and generate inconsistent dosing.

Taste-masking system

Cefuroxime axetil suspension requires a coordinated taste-masking system because bitterness can drive nonadherence. The most practical approaches are:

1. Particle coating with a taste-masking polymer.
2. Granulation with sweeteners and flavor.
3. Controlled-release or lipid-based taste barriers.
4. Ion-exchange or complexation approaches where technically compatible.

Sucrose provides bulk sweetness and viscosity but increases caloric load and may complicate use in some pediatric populations. High-intensity sweeteners can reduce sugar content, but their aftertaste and regional regulatory status must be assessed.

Fruit flavors, including citrus and berry systems, should be selected against the drug’s bitterness profile rather than used as a standalone masking solution.

Reconstitution and packaging

Powder-for-reconstitution products can improve shelf stability before use. Commercial differentiation may come from:

• A ready-to-use suspension with improved in-use stability.
• A low-volume powder with a calibrated oral syringe.
• A bottle design that reduces powder retention.
• A formulation that remains homogeneous for a longer in-use period.
• Unit-dose sachets or stick packs for institutional and travel use.

The reconstitution water volume, final solids content, preservative system, and bottle geometry directly affect dose uniformity.

What formulation patents could protect cefuroxime axetil products?

The original cefuroxime axetil patent estate is no longer a meaningful barrier to ordinary generic entry in major markets. A historical core patent, U.S. Patent No. 4,562,181, covered cefuroxime derivatives and dates from the early commercial development period. Its patent term expired decades ago.

New patent value would need to come from a narrowly defined formulation or manufacturing invention, such as:

• A specific particle-size distribution that improves dissolution.
• A stable amorphous or co-amorphous form.
• A defined surfactant-disintegrant ratio.
• A taste-masked particle architecture.
• A moisture-controlled granulation process.
• A suspension with defined redispersion performance.
• A low-sugar or sugar-free pediatric formulation.
• A packaging system that preserves stability after reconstitution.
• A manufacturing process that reduces hydrolysis or impurity formation.

A patent claiming only a conventional mixture of cefuroxime axetil with standard excipients would face substantial obviousness and enablement risk. Stronger claims should connect the excipient combination to measurable performance, such as dissolution, impurity control, stability, bioavailability, or dose uniformity.

When did cefuroxime axetil lose market exclusivity?

Cefuroxime axetil lost its meaningful small-molecule exclusivity in the United States long ago. The original Ceftin approval dates to 1987, and the five-year new chemical entity exclusivity period ended in the early 1990s. The relevant core patent protection also expired in the early 2000s.

Milestone	Approximate timing
Original cefuroxime axetil patent filings	Early 1980s
U.S. core patent issuance	1985
U.S. Ceftin approval	1987
Five-year NCE exclusivity end	1992
Core U.S. patent expiration	2002
Broad generic availability	Established for many years

Current market access depends primarily on abbreviated new drug application requirements, product-specific labeling, manufacturing compliance, bioequivalence, and local regulatory rules rather than on originator patent protection.

What is the Orange Book status of cefuroxime axetil?

Cefuroxime axetil is a conventional small-molecule generic product and is not a biologic subject to biosimilar interchangeability rules. The relevant FDA pathway is an ANDA referencing the listed drug, generally through dosage-form-specific bioequivalence and pharmaceutical equivalence requirements.

Orange Book considerations include:

• Tablet and oral suspension presentations.
• Strength-specific listings.
• Reference-listed drug status.
• Any active patent or exclusivity entries associated with a specific listed product.
• Product-specific labeling and therapeutic equivalence codes.

The commercial relevance of current Orange Book listings is narrower than for recently approved products because the core compound and principal dosage forms have been genericized for many years. A sponsor should still assess active listings before filing or launching because formulation-specific patents, labeling claims, or product-level entries can affect launch timing.

Are Paragraph IV challenges and generic litigation material?

The primary Paragraph IV opportunity for cefuroxime axetil occurred during the original genericization period. Current commercial risk is more likely to involve ordinary ANDA competition, manufacturing interruptions, supply contracts, or formulation differentiation than a new challenge to an active composition-of-matter patent.

Potential litigation can still arise over:

• A newly issued formulation patent.
• A method-of-use patent tied to a specific infection or dosing regimen.
• Trade dress or labeling claims.
• Manufacturing-process patents.
• Alleged infringement involving particle engineering or taste masking.

A formulation patent should be drafted with multiple claim layers: composition, particle attributes, manufacturing process, dissolution profile, stability profile, and dosage form. A single narrow excipient claim is more vulnerable to design-around.

Does cefuroxime axetil have biosimilar risk?

No. Biosimilar regulation applies to biological products, not cefuroxime axetil. Cefuroxime axetil faces generic competition under small-molecule ANDA pathways.

The relevant competitive variables are:

• Tablet versus suspension availability.
• Strength and pack-size coverage.
• Pediatric acceptability.
• Contract manufacturing cost.
• Tender pricing.
• Supply continuity.
• Regional registration.
• Hospital and pharmacy substitution.

What commercial opportunities exist for cefuroxime axetil?

Pediatric formulation

A palatable suspension with reliable redispersion and a low-sugar profile is the most direct product opportunity. An oral syringe, clear dosing instructions, and a formulation that minimizes sedimentation can support institutional and retail differentiation.

Improved dissolution

A formulation that achieves rapid and reproducible dissolution without high surfactant loading could support a product-specific patent and reduce variability between manufacturing sites.

Potential technologies include:

• Micronization.
• Spray drying.
• Amorphous solid dispersions.
• Lipid-based systems.
• Coated particles.
• Co-processed excipients.

Each technology must be evaluated against the risk of converting the prodrug to cefuroxime or increasing impurity formation.

Modified packaging

High-barrier unit-dose packaging can reduce moisture exposure and improve stability in hot and humid markets. Reconstitution systems with integrated dosing devices may have value in emerging markets and hospital settings.

Geographic expansion

Cefuroxime axetil remains commercially relevant in markets where second-generation cephalosporins are widely prescribed and pediatric oral antibiotics are in demand. Opportunities may exist through:

• Local licensing.
• Regional manufacturing.
• Government tenders.
• Dual registration of tablets and suspension.
• Contract development and manufacturing partnerships.

Licensing value is more likely to attach to a differentiated formulation, manufacturing process, or regional supply platform than to the active ingredient itself.

How does cefuroxime axetil compare with competing oral antibiotics?

Product	Main formulation issue	Patent position	Commercial differentiation
Cefuroxime axetil	Low solubility, food effect, bitter suspension	Legacy protection expired	Pediatric suspension, supply reliability
Amoxicillin/clavulanate	Moisture sensitivity and clavulanate stability	Generic competition	Broad pediatric and adult dosage range
Cefpodoxime proxetil	Poor solubility and suspension taste	Generic competition	Alternative oral cephalosporin positioning
Cefixime	Suspension palatability and dose volume	Generic competition	Once-daily dosing in selected regimens
Cephalexin	Better-established oral use and simpler formulation	Generic competition	Low-cost, familiar generic

Cefuroxime axetil can compete on spectrum, clinical positioning, and dosage-form execution. It is unlikely to compete solely through low manufacturing cost against large-scale generic suppliers.

What is the patent strength of a new cefuroxime axetil formulation?

The legacy active-ingredient estate is weak because the core patents have expired. A new formulation estate can be moderate to strong if it demonstrates a technically meaningful result that is difficult to reproduce through routine formulation work.

The strongest patent positions would combine:

• Narrow but commercially useful particle or excipient definitions.
• Comparative dissolution or bioavailability data.
• Improved impurity or stability profiles.
• Reproducible manufacturing parameters.
• Claims covering both tablets and suspension where support exists.
• International filings in high-value generic markets.

A patent based only on standard excipients at conventional concentrations is likely to have limited enforcement value.

What generic launch scenarios exist?

Low-cost conventional generic

This approach uses established excipients and standard tablets or suspension granules. It offers the fastest route to market but faces intense price competition.

Premium pediatric product

This approach focuses on taste masking, low sugar, oral-syringe dosing, and improved redispersion. It may support higher margins in private markets and selected hospital channels.

Regional supply platform

A manufacturer can combine local production, dual dosage forms, and tender participation. The commercial advantage is supply continuity rather than patent exclusivity.

Technology-backed formulation

A sponsor can use particle engineering, solid dispersion, or moisture-control technology to seek formulation patents and differentiate bioavailability or stability. Development cost and regulatory complexity are higher.

Key Takeaways

• Cefuroxime axetil is an off-patent small-molecule antibiotic with established generic competition.
• The main technical challenges are poor solubility, food-sensitive absorption, hydrolysis risk, moisture control, and bitter taste.
• Tablet opportunities center on wetting, rapid disintegration, low-moisture processing, and dissolution consistency.
• Suspension opportunities center on taste masking, redispersion, viscosity control, dosing accuracy, and in-use stability.
• Biosimilar risk does not apply; competition occurs through ANDA-style generic pathways.
• The strongest new patent opportunities involve measurable formulation or manufacturing advantages, not ordinary excipient combinations.
• Commercial value is highest in pediatric products, high-barrier packaging, regional licensing, and reliable supply.
• A conventional low-cost generic has limited differentiation unless it achieves superior manufacturing economics or supply performance.

FAQs

Can cefuroxime axetil be formulated as a sugar-free suspension?

Yes. A sugar-free suspension can use high-intensity sweeteners, polyols, polymeric suspending agents, flavors, and coated drug particles. The formulation must address aftertaste, viscosity, preservative compatibility, and dose uniformity.

Does sodium lauryl sulfate improve cefuroxime axetil bioavailability?

It can improve wetting and dissolution, but the effect depends on concentration, particle size, granulation, and the complete formulation. Higher surfactant levels can create tolerability and stability concerns.

Is cefuroxime axetil suitable for an orally disintegrating tablet?

It may be technically feasible, but bitterness, dose strength, tablet mass, moisture sensitivity, and mechanical robustness are important constraints. Taste-masked particles and moisture-protective packaging would likely be required.

Can a cefuroxime axetil formulation receive pediatric regulatory exclusivity?

A qualifying pediatric study may support regulatory exclusivity under applicable jurisdictional rules, but the availability and duration depend on the regulatory authority, study request, and approved labeling. The exclusivity would attach to the regulatory program, not restore composition-of-matter patent rights.

What is the most defensible formulation patent strategy for cefuroxime axetil?

The strongest strategy usually combines a defined particle or excipient system with data showing improved dissolution, stability, taste masking, bioavailability, or suspension performance. Broad claims to routine excipient combinations are less defensible.

References

1. AstraZeneca. (2008). Ceftin (cefuroxime axetil) tablets and oral suspension prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Patent No. 4,562,181. (1985). Cefuroxime derivatives. United States Patent and Trademark Office.

5. European Medicines Agency. (n.d.). Cefuroxime axetil product information. EMA.

6. World Health Organization. (2015). The International Pharmacopoeia: Cefuroxime axetil. World Health Organization.